We’re hearing more and more stories about insurance companies forcing patients to change from medications they are doing well on to less expensive medications, in spite of their wishes or those of their doctors. While that usually is not a problem, we’re hearing about more and more adverse events resulting from these medication changes (non-medical …
Read MoreArchives
StopAfib.org participated in a video series for those living with afib. The latest video, The Top Things You Need to Know When Taking an Anticoagulant, was released on September 29 for World Heart Day. To learn more, and watch the video, go to: StopAfib.org Participates in New Video Series About Atrial Fibrillation and Stroke Risk
Read MoreWe’re finally getting a glimpse into what to expect from edoxaban, the 4th new anticoagulant medication. At the European Society of Cardiology in Amsterdam, it was reported that edoxaban was safer--in other words, had less bleeding--than warfarin for those with deep vein thrombosis (blood clots in the legs) or pulmonary embolism (blood clots in the …
Read MoreStopAfib interviews Dr. James Reiffel Find a transcript and more on Dr. Reiffel at: www.stopafib.org In this video interview at Heart Rhythm 2012, Dr. James Reiffel updates us on new directions in drug treatments for atrial fibrillation. He talks about the combination of ranolazine (Ranexa) and dronedarone (Multaq), both used …
Read MoreAt Heart Rhythm 2012, Dr. Albert Waldo shared with StopAfib.org’s Mellanie True Hills about why aspirin should no longer be used for the prevention of stroke in atrial fibrillation. Dr. Waldo noted that many global afib guidelines have been revised, or soon will be, to remove aspirin as a recommended atrial fibrillation stroke prevention treatment. …
Read MoreStopAfib.org interviews Dr. Albert Waldo of Case Western Reserve University Find more information on this topic, and Dr. Waldo, at: www.stopafib.org In this video interview at Heart Rhythm 2012, Dr. Albert Waldo, one of the world's foremost atrial fibrillation treatment experts, discusses why aspirin no longer plays a role in …
Read MoreStopAfib.org interviews Dr. Daniel Singer of Harvard Medical School. Find more information on this topic, and Dr. Singer, at: http://www.stopafib.org/newsitem.cfm/NEWSID/397 Dr. Singer led a symposium on atrial fibrillation stroke prevention at Boston Atrial Fibrillation Symposium 2012. In this video interview, Dr. Singer shared with StopAfib.org information from that symposium. He provided an update on rivaroxaban …
Read MoreIn this interview, Dr. Daniel Singer updates us on the new anticoagulants for atrial fibrillation stroke prevention that he presented about at Boston Atrial Fibrillation Symposium. He provided an update on rivaroxaban (Xarelto), apixaban (Eliquis), dabigatran (Pradaxa), and edoxaban, and mentioned that all were better than warfarin (Coumadin) in preventing intracranial bleeding (bleeding in the …
Read MoreDr. John Mandrola shares a great update on the latest info regarding dabigatran (Pradaxa, Pradax). Dr. Mandrola not only treats atrial fibrillation patients, but he has also experienced afib himself. I have become an AF-doctor. That means my most exciting aspect of medicine is terminating AF with watts delivered through a catheter. “Got it.” In …
Read MoreA new study exploring ethnic differences in stroke risk for people with atrial fibrillation (AF) showed that Mexican American stroke survivors with afib were more than twice as likely to have another stroke as comparable non-Hispanic white stroke survivors with afib. Researchers were surprised by the study’s finding that severity of recurrent stroke is also …
Read More